CSF1 and neoplasm: Another study, which used CRISPR-Cas9 CSF-1 knockout murine breast (4T1) and colon (MC38) carcinoma models, showed that the inhibition of CSF-1R signaling boosts an immune-permissive TME, and results in improved tumor control compared to mice with parental tumors.